Tony Coles, Cerevel CEO
February 22, 2023 11:16 AM ESTUpdated February 24, 10:21 AM
People
R&D

Cerev­el blames Covid for de­layed neu­ro­science stud­ies, says pres­i­dent is leav­ing

Kyle LaHucik

Senior Reporter

Neu­ro­science biotech Cerev­el Ther­a­peu­tics said da­ta read­outs for sev­er­al clin­i­cal tri­als will come lat­er than orig­i­nal­ly ex­pect­ed, and al­so dis­closed the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times